Quince Therapeutics, Inc. Insider Trading
QNCX
Insiders sold 174K and bought nothing on the open market.
None of the selling was scheduled in advance under a 10b5-1 plan. Director Luca Benatti sold 174K on Dec 26, 2025, 56% of their stake, outside a plan. The last open-market buy by an executive or director was in Aug 2024.
Get an email when QNCX's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| Dec 26, 2025 | Luca Benatti Director | SoldNo plan | 50,000 | $3.47 | 174K | 56% | Form 4 |
- Dec 26, 2025No planLuca BenattiDirector · sold 50,000 at $3.47174K56% of stake
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with QNCX
Spot a number that looks wrong? Check it in QNCX's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing QNCX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.